performed the preclinical study to investigate the effect of DZP, VPA, and LEV alone, and the efficacy of LEV as an add-on treatment with DZP on the SE-induced neuronal death.
Experimental procedures

Experimental animals and chemicals
This study utilized the progeny of Sprague-Dawley (SD) rats (male, 9-11 weeks old) obtained from Experimental Animal Center, Hallym University, Chunchon, South Korea. The animals were provided with a commercial diet and water ad libitum under controlled temperature, humidity and lighting conditions (22 AE 2 8C 55 AE 5% and a 12:12 light/dark cycle with lights). Procedures involving animals and their care were conducted in accord with our institutional guidelines that comply with NIH Guide for the Care and Use of Laboratory Animals (National Institutes of Health (NIH) Guide for the Care and Use of Laboratory Animals, NIH Publications No. 1996) . In addition, we have made all efforts to minimize the number of animals used and their suffering. All reagents were obtained from Sigma (MO, USA), except as noted.
Seizure induction and drug treatments
Animals were given LiCl (Sigma-Aldrich Co., St. Louis, MO, USA; 3 mEq/kg i.p.) 24 h before the pilocarpine treatment. Animals were i.p. treated with pilocarpine (Sigma-Aldrich Co., St. Louis, MO, USA; 30 mg/kg i.p.) 20 min after atropine methylbromide (SigmaAldrich Co., St. Louis, MO, USA; 5 mg/kg i.p.) and were placed in individual observation chambers where seizure activity was scored according to the system of Racine. 10 Animals that entered SE typically did so within 20-30 min of the administration of pilocarpine and exhibited continuous seizure activity between 2 and 5 on the Racine scale (including akinesia, facial automatisms, limbic seizures consisting of forelimb clonus with rearing, salivation, masticatory jaw movements, and falling). One of the following drugs (n = 14 per group) was administered 2 h after onset of SE; (1) DZP (Valium, Hoffman Ia Roche, Neuilly sur-Seine, France; 10 mg/kg i.p.), (2) LEV (UCB, Belgium, 50, 100, and 150 mg/kg, i.p., respectively), (3) VPA (50, 100, and 150 mg/kg, i.p., respectively), (4) DZP (10 mg/kg, i.p.) + LEV (50, 100, and 150 mg/kg, i.p., respectively), (5) DZP (10 mg/kg, i.p.) + VPA (50, 100, and 150 mg/kg, i.p., respectively), and (6) DZP (10 mg/kg, i.p.) + oxiracetam (OXI, 50, 100, and 150 mg/kg, i.p., respectively). The dosage of each drug was chosen based on its anticonvulsive concentration to control seizure activity induced by SE in the preliminary study and our previous study. 11 In addition, OXI was chosen as a comparison drug for LEV, because OXI has the similar chemical structures of LEV. Fig. 1 shows the effect of each compound on behavioral seizure activity within 30 min after injection and mortality.
Tissue processing
In our previous study, neuronal damage in the hippocampus was noticeable at 3-4 days after SE. 3 Therefore, we determined 4 days after SE as the best time point to evaluate neuronal damage induced by SE.
3 Animals (n = 5 per group) were perfused transcardially with phosphate-buffered saline followed by 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4) under urethane anesthesia (Sigma-Aldrich Co., St. Louis, MO, USA; 1.5 g/ kg, i.p.) for 20 min. The brains were removed, and postfixed in the same fixative for 4 h. The brain tissues were cryoprotected by infiltration with 30% sucrose overnight. Thereafter, the entire hippocampus was frozen and sectioned with a cryostat at 30 mm and consecutive sections were placed in six-well plates containing PBS. For stereological study, every sixth section in the series throughout the entire hippocampus was used for evaluation of neuronal damage. 12 
Fluoro-Jade B staining
Fluoro-Jade B (FJB) staining was used to identify degenerating neurons. Briefly, sections were rinsed in distilled water, and mounted onto gelatin-coated slides and then dried on a slide warmer. The slides were immersed in 100% ethanol for 3 min, followed by 70% ethanol for 2 min and distilled water for 2 min. The slides were then transferred to 0.06% potassium permanganate for 15 min and gently agitated. After rinsing in distilled water for 2 min, the slides were incubated for 30 min in 0.001% FJB (HistoChem Inc. Jefferson, AR, USA), freshly prepared by adding 20 ml of a 0.01% stock FJB solution to 180 ml of 0.1% acetic acid, with gentle shaking in the dark. After rinsing for 1 min in each of three changes of distilled water, the slides were dried, dehydrated in xylene and coverslipped with DPX. For stereological study, every sixth section in the series throughout the entire hippocampus was used (see below).
Stereology
Hippocampal volumes (V) were estimated according to a formula based on the modified Cavalieri method: Fig. 1 . The effect of each compound on behavioral seizure activity (within 30 min after injection) and mortality (until 4 days after injection). There is no differences of the inhibitory effect of behavioral seizure activity from each compound (n = 14 per group). ssf is the fraction of the sections sampled or section sampling fraction (of 1/6 in this study). The subfield areas were delineated with a 2.5Â objective lens. The volumes are reported as mm 3 . 13 The optical fractionator was used to estimate cell numbers. The optical fractionator (a combination of performing counting with the optical disector, with fractionator sampling) is a stereological method based on a properly designed systematic random sampling method that by definition yields unbiased estimates of population number. The sampling procedure is accomplished by focusing through the depth of the tissue (the optical disector height, h; of 15 mm in all cases for this study). The number of each cell type (C) in each of the subregions is estimated as:
À is the number of cells actually counted in the disectors that fall within the sectional profiles of the subregion seen on the sampled sections, and asf is the area sampling fraction calculated as the area of the counting frame of the dissector, a(frame) (50 mm Â 50 mm in this study) and the area associated with each x, y movement, grid (x, y step) (250 mm Â 250 mm in this study) {asf = [a(frame)/a(x, y step)]}. FJB-positive cells were counted with a 40Â objective lens. All FJB-positive cells were counted regardless the intensity of labeling. Therefore, the total number of cells was corrected by multiplying with appropriate correction factors (CF) representing the degree of shrinkage (or swelling) compared with the non-SE animals. Cell counts were performed by two different investigators who were blind to the classification of tissues. 12 
Volumetry for vasogenic edema
In our previous study, vasogenic edema and neuronal damage in the PC were noticeable at 1 day and 3 days after SE, respectively. 13 Therefore, we determined that 3 days after SE was the best time point to evaluate the effect of test drugs on vasogenic edema induced by SE. Three days after SE, animals (n = 5 per group) were perfused by the same method described above. To measure vasogenic edema lesion, sections were reacted for serum-proteins using horse anti-rat IgG (Vector, USA) in PBS containing 0.3% Triton X-100 and 2% normal goat serum overnight at room temperature. After washing three times for 10 min with PBS, sections were incubated in ABC complex (Vector, USA), diluted 1:200 in the same solution. Between the incubations, the tissues were washed with PBS three times for 10 min each. The sections were visualized with 3,3 0 -diaminobenzidine (DAB) in 0.1 M Tris buffer and mounted on the gelatin-coated slides. The immunoreaction was observed under the Axioscope microscope (Carl Zeiss, Germany). Thereafter, volume of vasogenic edema lesion (V) were estimated according to a formula based on the modified Cavalieri method:
where a is area of the region of the delineated subfield measured by AxioVision Rel. 4.8 software, t nom is the nominal section thickness (of 30 mm in this study), and ssf is the fraction of the sections sampled or section sampling fraction (of 1/6 in this study). The subfield areas were delineated with a 2.5Â objective lens. The volumes are reported as mm 3 .
13,14
Statistical analysis
All data obtained from the quantitative measurements were analyzed using one-way ANOVA to determine statistical significance. Bonferroni's test was used for post hoc comparisons. A pvalue below 0.05 was considered statistically significant. 2 
Results
The effect of LEV alone on SE-induced neuronal death
In the DZP-treated group, the numbers of FJB positive degenerative neurons per mm 3 in CA1-, CA3 pyramidal cells, and dentate hilar neurons were 24,318 AE 1993, 13,182 AE 2314, and 14,545 AE 2443, respectively ( Fig. 2A, E) . In the LEV-50 mg/kg treated group, the numbers of FJB positive degenerative neurons per mm 3 in CA1-, CA3 pyramidal cells, and dentate hilar neurons were 7341 AE 983, 20,136 AE 7069, and 9705 AE 766, respectively (Fig. 2B , E). These findings indicate that LEV-50 mg/kg treatment may effectively reduce the SE-induced neuronal death in CA1 pyramidal cells and dentate hilar neurons (not CA3 pyramidal cells) as compared to DZP treatment (p < 0.05; Fig. 2B and E). LEV-100 mg/kg treatment (Fig. 2D, E) . Therefore, LEV-150 mg/kg treatment could effectively reduce FJB positive degenerative neurons only in CA3 pyramidal cells (p < 0.05) as compared to LEV-100 mg/kg treatment. pyramidal cell layer; Panels 3, Dentate hilus. As compared to LEV single treatment, LEV add-on treatment with DZP exacerbates neuronal damage induced by SE. Bar = 50 mm.
(G) The quantitative analysis of neuronal damage after SE (mean AE S.D.). Significant differences from the same dose of LEV-treated animals, *p < 0.05 (n = 5 per group).
These findings indicate that the LEV alone could effectively prevent neuronal damage from SE.
The effect of VPA alone on SE-induced neuronal death
In the VPA-50 mg/kg treated group, the numbers of FJB positive degenerative neurons per mm 3 in CA1-, CA3 pyramidal cells, and dentate hilar neurons were 18,333 AE 3489, 15,758 AE 3624, and 14,894 AE 3248, respectively. These findings indicate that VPA-50 mg/kg treatment may not be effective to reduce the SE-induced neuronal death as compared to DZP treatment (Fig. 3A, B 
The effect of LEV as an add-on drug on SE-induced neuronal death
In the DZP + LEV-50 mg/kg treated group, the numbers of FJB positive degenerative neurons per mm 3 in CA1-, CA3 pyramidal cells, and dentate hilar neurons were 33,227 AE 4023, 30,000 AE 10,391, and 12,773 AE 5510, respectively. These results indicated that co-treatment of DZP + LEV-50 mg/kg might exacerbate SE-induced neuronal damage in CA1 pyramidal cells as compared to DZP alone (p < 0.05; Fig. 4B, G) , and LEV-50 mg/kg alone (p < 0.05; Fig. 4A, G) . In addition, co-treatment of DZP + LEV-100 mg/kg groups showed the numbers of FJB positive degenerative neurons per mm 3 in CA1-, CA3 pyramidal cells, and dentate hilar neurons were 15,068 AE 4326, 18,364 AE 9663, and 15,864 AE 1132, respectively (Fig. 4D, G) . In the DZP + LEV-150 mg/kg treated group, the numbers of FJB positive degenerative neurons per mm 3 in CA1-, CA3 pyramidal cells, and dentate hilar neurons were 13,091 AE 2097, 17,212 AE 1627, and 11,091 AE 1969, respectively (Fig. 4F, G) . These results revealed that cotreatment of DZP + LEV might aggravate SE-induced neuronal damage as compared to LEV alone (p < 0.05; Fig. 4G ). In other words, DZP cotreatment could alleviate neuroprotective effect of LEV against SE. 
The effect of OXI as an add-on drug on SE-induced neuronal death
In the DZP + OXI-50 mg/kg treated group, the numbers of FJB positive degenerative neurons per mm 3 in CA1-, CA3 pyramdical cells, and dentate hilar neurons were 1523 AE 422, 2818 AE 1222, and 1682 AE 558, respectively (Fig. 5A, D) . In addition, co-treatment of DZP + OXI-100 mg/kg groups showed the numbers of FJB positive degenerative neurons per mm 3 in CA1-, CA3 pyramidal cells, and dentate hilar neurons were 1205 AE 172, 2121 AE 367, and 2394 AE 845, respectively (Fig. 5B, D) . Unlike LEV, these results indicated that cotreatment of DZP + OXI-50 mg/kg, and +OXI-100 mg/kg might alleviate SE-induced neuronal damage as compared to DZP alone (p < 0.05; Fig. 5D ). In addition, these neuroprotective effects of OXI did not show dose-dependent manners. However, DZP + OXI-150 mg/ kg treated group showed the increase in the degree of SE-induced neuronal death, as compared to DZP treated group; the numbers of FJB positive degenerative neurons per mm 3 in CA1-, CA3 pyramdical cells, and dentate hilar neurons were 25,576 AE 1863, 17,803 AE 4693, and 12,682 AE 2136, respectively (Fig. 5C, D) . These results indicate that co-treatment of LEV-like drugs with DZP may alleviate or aggravate SE-induced neuronal damage dependent on their dosages.
The effect of VPA as an add-on drug on SE-induced neuronal death
In the DZP + VPA-50 mg/kg treated group, the numbers of FJB positive degenerative neurons per mm 3 in CA1-, CA3 pyramidal cells, and dentate hilar neurons were 14,258 AE 2450, 10,530 AE 3683, and 11,727 AE 1473, respectively. These results indicated that co-treatment of DZP + VPA-50 mg/kg might alleviate SE-induced neuronal damage in CA1-, and CA3 pyramidal cells, as compared to VPA alone (p < 0.05; Fig. 2B, C) , and VPA-50 mg/kg alone (p < 0.05; Fig. 6A , B and G). Co-treatment of DZP + VPA-100 mg/kg groups showed the numbers of FJB positive degenerative neurons per mm 3 in CA1-, CA3 pyramidal cells, and dentate hilar neurons were 10,841 AE 1024, 9818 AE 3522, and 6432 AE 1768, respectively. In the DZP + VPA-150 mg/kg treated group, the numbers of FJB positive degenerative neurons per mm 3 in CA1-, CA3 pyramidal cells, and dentate hilar neurons were 12,745 AE 3161, 10,873 AE 1287, and 7473 AE 2429, respectively. These results revealed that co-treatment of DZP + VPA-100 mg/kg, and +VPA-150 mg/kg might restrictedly reduce SE-induced neuronal damage (in dentate hilar neurons) as compared to VPA alone (p < 0.05; Fig. 6C-G ).
The effects of test drugs on SE-induced vasogenic edema
In the DZP-treated group, volume of vasogenic edema was 19. 4 , respectively. Furthermore, the numbers of FJB positive degenerative neurons in PC neurons were not different from each group. Therefore, there was no protective effect of each test drug (alone or as add-on) from SE-induced vasogenic edema formation and nueornal damage in the PC compared to DZP (Fig. 7) .
Discussion
The major findings of the present study are that LEV has neuroprotective effect from SE-induced neuronal death, but not vasogenic edema, as a single treatment or an add-on drug. LEV has a wide spectrum of action and a favorable pharmacokinetic profile. The mechanism of its action is distinct from that of classic AEDs and unrelated to known mechanisms of neurotransmission but seems to involve the synaptic vesicle protein 2A. 15 In addition, LEV inhibits HVA-Ca 2 channels (N-type), reverses the inhibition of negative allosteric modulators such as zinc and b-carbolines of g-aminobutyric acid (GABA)-and glycine-gated currents, and reduces the calcium release from intraneuronal stores. 15 Furthermore, neuroprotective effects of LEV have been described in animal models. 16 In the present study, LEV (!50 mg/kg) was significantly effective to protect neuronal damage from SE in comparison to DZP and VPA. However, it is noticeable that LEV as an add-on drug with DZP could not alleviate SE-induced neuronal damage as compared to LEV alone, and showed the similar effect of DZP alone. VPA (!100 mg/kg) was significantly effective to protect neuronal damage from SE, as compared to DZP. In contrast to LEV, VPA (50 and 100 mg/kg) as an add-on drug with DZP significantly reduced SE-induced neuronal damage as compared to DZP alone, and showed the similar effect of VPA (150 mg/kg) alone. These findings indicate that, unlike VPA, LEV may negatively interact with DZP. This hypothesis is supported by our other study using OXI, a chemical analog of LEV. Similar to LEV, co-treatment of OXI (150 mg/kg) and DZP exacerbated SE-induced neuronal death as compared to OXI alone. Based on these findings, it is likely that analogs of LEV including OXI and piracetam may interact with BDZ family. Therefore, our findings suggest that LEV may be more effective to prevent SE-induced neuronal death as a first line drug than as a second line therapy after BDZ treatment, and that LEV as an add-on drug with BDZ may not provide any additional benefit to outcome of SE.
One the other hand, the efficacy of LEV and VPA in SE-induced neuronal death showed regional specific manners (CA1 pyramidal cells > dentate hilar cell > CA3 pyramidal cells). These discrepancies would be resulted from differential susceptibility of hippocampal neurons to a kind of insults. Although dentate granule cells are remarkably resistant to neuronal damage caused by most insults, including hypoxia/ischemia and seizures, dentate hilar neurons are vulnerable to seizure-induced damage.
3 CA3 pyramidal neurons are extremely sensitive to seizure-induced or traumainduced damage, and CA1 pyramidal neurons are susceptible to both hypoxia/ischemia-and seizure-induced neurodegeneration. 17 Following DZP treatment, electroencephalogram exhibits the frequent occurrence of interictal spikes and occasionally sustained ictal discharges until 2 days after SE without behavioral seizure activity. 18 Therefore, it would not be excluded that the distinct effect of each compound on long-lasting electroencephalographic seizure activity may result in regional specific patterns of SE-induced neuronal death. Further studies are needed to elucidate the role of AEDs in regional specific neuronal injuries.
